DiaMedica appoints former Medtronic CMO Richard Kuntz to Board of Directors

DiaMedica Therapeutics Inc.

Dr. Kuntz appointed effective May 30, 2023; he recently retired as Medtronic's Chief Medical and Scientific Officer.
He received an option to purchase 32,320 voting common shares at fair market value, vesting quarterly over 3 years.
Kuntz will receive standard non-employee director compensation and a standard indemnification agreement.
His expertise in stroke and clinical trial design aligns with DiaMedica's ReMEDy2 acute ischemic stroke trial.
Kuntz founded the Harvard Clinical Research Institute and served on boards of ZimVie and Identiv.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.